Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

AMS vs ARAY vs NVCR vs GKOS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AMS
American Shared Hospital Services

Medical - Care Facilities

HealthcareAMEX • US
Market Cap$13M
5Y Perf.+9.2%
ARAY
Accuray Incorporated

Medical - Devices

HealthcareNASDAQ • US
Market Cap$35M
5Y Perf.-86.0%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-75.0%
GKOS
Glaukos Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$7.85B
5Y Perf.+244.2%

AMS vs ARAY vs NVCR vs GKOS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AMS logoAMS
ARAY logoARAY
NVCR logoNVCR
GKOS logoGKOS
IndustryMedical - Care FacilitiesMedical - DevicesMedical - Instruments & SuppliesMedical - Devices
Market Cap$13M$35M$1.92B$7.85B
Revenue (TTM)$29M$429M$674M$551M
Net Income (TTM)$-2M$-46M$-173M$-189M
Gross Margin25.0%26.8%75.2%78.1%
Operating Margin-12.3%-5.1%-27.2%-15.6%
Forward P/E6.1x
Total Debt$23M$176M$290M$140M
Cash & Equiv.$11M$57M$103M$91M

AMS vs ARAY vs NVCR vs GKOSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AMS
ARAY
NVCR
GKOS
StockMay 20May 26Return
American Shared Hos… (AMS)100109.2+9.2%
Accuray Incorporated (ARAY)10014.0-86.0%
NovoCure Limited (NVCR)10025.0-75.0%
Glaukos Corporation (GKOS)100344.2+244.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: AMS vs ARAY vs NVCR vs GKOS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AMS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Glaukos Corporation is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
AMS
American Shared Hospital Services
The Growth Play

AMS carries the broadest edge in this set and is the clearest fit for growth exposure.

  • Rev growth 32.9%, EPS growth 245.9%, 3Y rev CAGR 17.1%
  • 32.9% revenue growth vs ARAY's 2.7%
  • -7.6% margin vs GKOS's -34.3%
  • -3.8% ROA vs GKOS's -20.1%, ROIC -5.8% vs -9.2%
Best for: growth exposure
ARAY
Accuray Incorporated
The Specific-Use Pick

ARAY plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
NVCR
NovoCure Limited
The Secondary Option

NVCR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
GKOS
Glaukos Corporation
The Income Pick

GKOS is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.

  • beta 1.20
  • 457.1% 10Y total return vs NVCR's 30.3%
  • Lower volatility, beta 1.20, Low D/E 21.3%, current ratio 4.69x
  • Beta 1.20, current ratio 4.69x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthAMS logoAMS32.9% revenue growth vs ARAY's 2.7%
Quality / MarginsAMS logoAMS-7.6% margin vs GKOS's -34.3%
Stability / SafetyGKOS logoGKOSBeta 1.20 vs ARAY's 2.42, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)GKOS logoGKOS+52.0% vs ARAY's -78.4%
Efficiency (ROA)AMS logoAMS-3.8% ROA vs GKOS's -20.1%, ROIC -5.8% vs -9.2%

AMS vs ARAY vs NVCR vs GKOS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AMSAmerican Shared Hospital Services
FY 2024
Rental Income from Medical Services
55.1%$16M
Patient Income
44.3%$13M
Equipment Sales
0.5%$155,000
ARAYAccuray Incorporated
FY 2025
Product
51.8%$238M
Service
48.2%$221M
NVCRNovoCure Limited

Segment breakdown not available.

GKOSGlaukos Corporation
FY 2019
Glaucoma
97.5%$231M
Corneal Health
2.5%$6M

AMS vs ARAY vs NVCR vs GKOS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLGKOSLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

GKOS leads this category, winning 4 of 6 comparable metrics.

NVCR is the larger business by revenue, generating $674M annually — 22.9x AMS's $29M. AMS is the more profitable business, keeping -7.6% of every revenue dollar as net income compared to GKOS's -34.3%. On growth, GKOS holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAMS logoAMSAmerican Shared H…ARAY logoARAYAccuray Incorpora…NVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…
RevenueTrailing 12 months$29M$429M$674M$551M
EBITDAEarnings before interest/tax$2M-$15M-$165M-$40M
Net IncomeAfter-tax profit-$2M-$46M-$173M-$189M
Free Cash FlowCash after capex-$10M-$28M-$48M-$18M
Gross MarginGross profit ÷ Revenue+25.0%+26.8%+75.2%+78.1%
Operating MarginEBIT ÷ Revenue-12.3%-5.1%-27.2%-15.6%
Net MarginNet income ÷ Revenue-7.6%-10.8%-25.7%-34.3%
FCF MarginFCF ÷ Revenue-34.7%-6.5%-7.1%-3.4%
Rev. Growth (YoY)Latest quarter vs prior year+2.5%-7.4%+12.3%+41.2%
EPS Growth (YoY)Latest quarter vs prior year-56.7%-6.1%-100.0%-6.3%
GKOS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ARAY leads this category, winning 2 of 4 comparable metrics.

On an enterprise value basis, AMS's 7.5x EV/EBITDA is more attractive than ARAY's 11.0x.

MetricAMS logoAMSAmerican Shared H…ARAY logoARAYAccuray Incorpora…NVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…
Market CapShares × price$13M$35M$1.9B$7.9B
Enterprise ValueMkt cap + debt − cash$25M$154M$2.1B$7.9B
Trailing P/EPrice ÷ TTM EPS6.09x-18.91x-13.80x-40.90x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate0.93x
EV / EBITDAEnterprise value multiple7.51x10.99x
Price / SalesMarket cap ÷ Revenue0.46x0.08x2.92x15.47x
Price / BookPrice ÷ Book value/share0.45x0.37x5.51x11.69x
Price / FCFMarket cap ÷ FCF
ARAY leads this category, winning 2 of 4 comparable metrics.

Profitability & Efficiency

AMS leads this category, winning 5 of 9 comparable metrics.

AMS delivers a -7.9% return on equity — every $100 of shareholder capital generates $-8 in annual profit, vs $-77 for ARAY. GKOS carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARAY's 2.17x. On the Piotroski fundamental quality scale (0–9), ARAY scores 6/9 vs GKOS's 3/9, reflecting solid financial health.

MetricAMS logoAMSAmerican Shared H…ARAY logoARAYAccuray Incorpora…NVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…
ROE (TTM)Return on equity-7.9%-77.5%-50.8%-26.5%
ROA (TTM)Return on assets-3.8%-10.1%-16.5%-20.1%
ROICReturn on invested capital-5.8%+3.0%-16.4%-9.2%
ROCEReturn on capital employed-6.4%+2.8%-28.9%-10.3%
Piotroski ScoreFundamental quality 0–95653
Debt / EquityFinancial leverage0.77x2.17x0.85x0.21x
Net DebtTotal debt minus cash$12M$119M$187M$49M
Cash & Equiv.Liquid assets$11M$57M$103M$91M
Total DebtShort + long-term debt$23M$176M$290M$140M
Interest CoverageEBIT ÷ Interest expense-1.35x-1.86x-96.80x-18.69x
AMS leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

GKOS leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in GKOS five years ago would be worth $16,155 today (with dividends reinvested), compared to $606 for ARAY. Over the past 12 months, GKOS leads with a +52.0% total return vs ARAY's -78.4%. The 3-year compound annual growth rate (CAGR) favors GKOS at 31.7% vs ARAY's -56.6% — a key indicator of consistent wealth creation.

MetricAMS logoAMSAmerican Shared H…ARAY logoARAYAccuray Incorpora…NVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…
YTD ReturnYear-to-date-4.3%-65.5%+28.3%+21.2%
1-Year ReturnPast 12 months-27.4%-78.4%+1.1%+52.0%
3-Year ReturnCumulative with dividends-28.0%-91.8%-75.7%+128.7%
5-Year ReturnCumulative with dividends-41.1%-93.9%-91.3%+61.5%
10-Year ReturnCumulative with dividends-4.7%-94.5%+30.3%+457.1%
CAGR (3Y)Annualised 3-year return-10.4%-56.6%-37.6%+31.7%
GKOS leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — AMS and GKOS each lead in 1 of 2 comparable metrics.

AMS is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than ARAY's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GKOS currently trades 91.4% from its 52-week high vs ARAY's 14.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAMS logoAMSAmerican Shared H…ARAY logoARAYAccuray Incorpora…NVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…
Beta (5Y)Sensitivity to S&P 500-0.02x2.42x2.20x1.20x
52-Week HighHighest price in past year$3.11$2.10$20.06$146.75
52-Week LowLowest price in past year$1.25$0.28$9.82$73.16
% of 52W HighCurrent price vs 52-week peak+64.6%+14.0%+83.9%+91.4%
RSI (14)Momentum oscillator 0–10063.858.469.863.0
Avg Volume (50D)Average daily shares traded138K1.4M1.5M678K
Evenly matched — AMS and GKOS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: NVCR as "Buy", GKOS as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 9.3% for GKOS (target: $147).

MetricAMS logoAMSAmerican Shared H…ARAY logoARAYAccuray Incorpora…NVCR logoNVCRNovoCure LimitedGKOS logoGKOSGlaukos Corporati…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$33.50$146.67
# AnalystsCovering analysts1524
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

GKOS leads in 2 of 6 categories (Income & Cash Flow, Total Returns). ARAY leads in 1 (Valuation Metrics). 1 tied.

Best OverallGlaukos Corporation (GKOS)Leads 2 of 6 categories
Loading custom metrics...

AMS vs ARAY vs NVCR vs GKOS: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is AMS or ARAY or NVCR or GKOS a better buy right now?

For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.

9% revenue growth year-over-year, versus 2. 7% for Accuray Incorporated (ARAY). American Shared Hospital Services (AMS) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — AMS or ARAY or NVCR or GKOS?

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.

5%, compared to -93. 9% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: GKOS returned +457. 1% versus ARAY's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — AMS or ARAY or NVCR or GKOS?

By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.

02β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately -15516% more volatile than AMS relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.

04

Which is growing faster — AMS or ARAY or NVCR or GKOS?

By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.

9% versus 2. 7% for Accuray Incorporated (ARAY). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — AMS or ARAY or NVCR or GKOS?

American Shared Hospital Services (AMS) is the more profitable company, earning 7.

7% net margin versus -37. 0% for Glaukos Corporation — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARAY leads at 1. 7% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — AMS or ARAY or NVCR or GKOS?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is AMS or ARAY or NVCR or GKOS better for a retirement portfolio?

For long-horizon retirement investors, American Shared Hospital Services (AMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02)). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMS: -4. 7%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between AMS and ARAY and NVCR and GKOS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AMS is a small-cap high-growth stock; ARAY is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

AMS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 14%
Run This Screen
Stocks Like

ARAY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

GKOS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 20%
  • Gross Margin > 46%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform AMS and ARAY and NVCR and GKOS on the metrics below

Revenue Growth>
%
(AMS: 2.5% · ARAY: -7.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.